StreetInsider.com News Articles

Form SCHEDULE 13G/A Cosmos Health Inc. Filed by: Bovopoulos Andreas

Fri, 30 Oct 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20261030/27266179.html

Form SCHEDULE 13G Cosmos Health Inc. Filed by: WELLS FARGO & COMPANY/MN

Thu, 29 Oct 2026 12:05:00 -0500

si-local-file:///var/storage/secattach/20261029/27255731.html

Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target

Wed, 28 Oct 2026 09:20:00 -0500

CHICAGO, IL / ACCESS Newswire / October 28, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Noble Capital Markets ("Noble") has initiated company-sponsored equity research coverage on the Company with an Outperform rating and a price target of $1.40 per share.

The research report, authored by Noble Capital Markets Senior Research Analyst Michael Kupinski, is available on Channelchek, along with the latest news, market data,

Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target

Wed, 28 Oct 2026 09:20:00 -0500

The research report, authored by Noble Capital Markets Senior Research Analyst Michael Kupinski, is available on Channelchek, along with the latest news, market data,

Noble Capital Starts (COSM) at Outperform

Mon, 26 Oct 2026 08:24:23 -0500

Noble Capital analyst Michael Kupinski initiates coverage on (NASDAQ: COSM) with a Outperform rating and a price target of $1.40.

The analyst comments "Initiating coverage with an Outperform rating. We believe Cosmos Health is positioned for a meaningful improvement in profitability as its revenue mix shifts toward higher-margin proprietary healthcare products and pharmaceutical manufacturing. The company's established wholesale distribution business provides a revenue base, while its expanding U.S. direct-to-consumer operations could become an increasingly important driver of earnings growth.:

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Shares of closed at

Noble Capital Starts (COSM) at Outperform

Mon, 26 Oct 2026 08:24:23 -0500

Noble Capital analyst Michael Kupinski initiates coverage on (NASDAQ: COSM) with a Outperform rating and a price target of $1.40.

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Shares of closed at

Cosmos Health launches e-commerce subscriptions in Oceania

Thu, 22 Oct 2026 15:56:29 -0500

Cosmos Health Inc. (NASDAQ: COSM) has expanded its direct-to-consumer e-commerce and subscription business to Australia, New Zealand, and the broader Oceania region, with sales already underway, according to a company statement.

Customers in the region can purchase Cosmos Health products through the company's online stores and opt into recurring delivery subscriptions at checkout.

The expansion follows growth in the company's U.S. direct-to-consumer business, which had 8,940 active subscriptions and 14,624 online checkout orders as of October 19, 2026.

Greg Siokas, CEO of Cosmos Health, said: "Our ambition is global. Oceania is an important next step, and we intend to keep expanding our reach,

Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway

Thu, 22 Oct 2026 15:55:00 -0500

CHICAGO, IL / ACCESS Newswire / October 22, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the expansion of its e-commerce and subscription business to Australia, New Zealand and the broader Oceania region. The business is now live across the region, and sales are already underway.

Expansion Overview

Customers across Australia, New Zealand and the broader Oceania region can now purchase Cosmos Health products directly through the Company's online stores, with the option to subscribe for recurring delivery at checkout.

Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway

Thu, 22 Oct 2026 15:55:00 -0500

Expansion Overview

Form 8-K Cosmos Health Inc. For: Oct 19

Thu, 22 Oct 2026 11:50:00 -0500

si-local-file:///var/storage/secattach/20261022/27221298.html

Cosmos Health reports record nine-month revenue, reaffirms $90M outlook

Tue, 20 Oct 2026 12:30:15 -0500

Cosmos Health Inc. (NASDAQ: COSM) reported preliminary nine-month revenue of approximately $54.3 million for 2026, a 19% increase year over year, according to a shareholder letter issued by Chief Executive Officer Greg Siokas.

The company reaffirmed its expectation that full-year 2026 revenue will surpass $90 million, implying fourth-quarter revenue of approximately $35.7 million, an increase of roughly 81% over the $19.7 million recorded in the fourth quarter of 2025. The figures are preliminary and unaudited.

Third-quarter revenue came in at approximately $17.4 million, which the company described as the highest third-quarter result in its history and up 40% from the same period

Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

Tue, 20 Oct 2026 12:15:00 -0500

CHICAGO, IL / ACCESS Newswire / October 20, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders, providing a 2026 business update.

Dear Fellow Shareholders,

2026 marks a defining moment in the evolution of Cosmos Health. For years, we have invested in pharmaceutical manufacturing, automated distribution, proprietary brands, technology and international expansion to build a vertically integrated global healthcare platform. Today, those investments are converging.

Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

Tue, 20 Oct 2026 12:15:00 -0500

Dear Fellow Shareholders,

Cosmos Health projects $15M in Q4 U.S. revenue as subscriptions rise 42%

Mon, 19 Oct 2026 09:31:45 -0500

Cosmos Health Inc. (NASDAQ: COSM) said it expects approximately $15 million in U.S. revenue for the fourth quarter ending December 31, 2026, with gross profit of approximately $10.5 million, according to a company statement issued October 19, 2026.

The company said active U.S. subscriptions reached 8,940 as of October 19, up 42% from 6,287 reported five days earlier on October 14. Monthly subscription value at standard renewal pricing rose 44% over the same period to approximately $1.3 million.

Subscription revenue is expected to account for approximately $11.5 million, or more than three-quarters, of the projected quarterly total. That figure includes approximately $8.2

Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in

Mon, 19 Oct 2026 09:30:00 -0500

CHICAGO, IL / ACCESS Newswire / October 19, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, based on its current growth trajectory, it expects U.S. revenue of approximately $15 million for the fourth quarter of 2026, with gross profit of approximately $10.5 million. Subscriptions are expected to generate more than three-quarters of fourth quarter U.S. revenue, and momentum toward this outlook continues to build: as of October 19, 2026, active U.S. subscriptions reached 8,940, up 42% from

Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in

Mon, 19 Oct 2026 09:30:00 -0500

Form SCHEDULE 13G/A Cosmos Health Inc. Filed by: Bovopoulos Andreas

Fri, 16 Oct 2026 16:32:00 -0500

si-local-file:///var/storage/secattach/20261016/27198303.html

Cosmos Health reports 6,287 U.S. subscriptions since mid-September launch

Wed, 14 Oct 2026 09:31:30 -0500

Cosmos Health Inc. (NASDAQ: COSM) reported that its U.S. online stores have reached 6,287 active subscriptions as of October 14, 2026, with substantially all of them added since mid-September 2026, following the launch of its subscription model in mid-July 2026.

According to a company statement, its subscription management platform has tracked 10,881 U.S. online checkout orders to date, of which 60.5% included a subscription. The company said the subscription rate has recently climbed above 75% of checkout orders.

The 6,287 active subscriptions comprise 12,408 subscription lines and 14,793 product units, averaging approximately 2.4 units per subscription. At standard renewal pricing, the aggregate

Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription

Wed, 14 Oct 2026 09:30:00 -0500

CHICAGO, IL / ACCESS Newswire / October 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has reached 6,287 active subscriptions in its U.S. online stores, substantially all of them added since mid-September 2026, following the launch of its subscription model in mid-July 2026. Overall, 60.5% of the U.S. online checkout orders tracked by the Company's subscription management platform have included a subscription, with adoption accelerating in recent days.

CHICAGO, IL / ACCESS Newswire / October 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has reached 6,287 active subscriptions in its U.S. online stores, substantially all of them added since mid-September 2026, following the launch of its subscription model in mid-July 2026. Overall, 60.5% of the U.S. online checkout orders tracked by the Company's subscription management platform have included a subscription, with adoption accelerating in recent days.

CHICAGO, IL / ACCESS Newswire / October 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its United States direct-to-consumer sales reached a record of more than $92,000 in a single day on October 11, 2026. Sales over the past 30 days totaled $902,000, while average daily sales over the past 10 days exceeded $60,000, double the 30-day average.

United States Direct-to-Consumer Sales

The figures cover sales through

Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days

Tue, 13 Oct 2026 09:30:00 -0500

CHICAGO, IL / ACCESS Newswire / October 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its United States direct-to-consumer sales reached a record of more than $92,000 in a single day on October 11, 2026. Sales over the past 30 days totaled $902,000, while average daily sales over the past 10 days exceeded $60,000, double the 30-day average.

United States Direct-to-Consumer Sales

The figures cover sales through

Form 8-K Cosmos Health Inc. For: Oct 07

Fri, 09 Oct 2026 17:00:00 -0500

si-local-file:///var/storage/secattach/20261009/27172158.html

Cosmos Health posts $54.3M in nine-month revenue, up 19%

Wed, 07 Oct 2026 09:45:17 -0500

Cosmos Health Inc. (NASDAQ: COSM) reported preliminary revenue of approximately $54.3 million for the nine months ended September 30, 2026, a 19% increase from $45.6 million in the same period of 2025, according to a company statement.

Third-quarter preliminary revenue came in at approximately $17.4 million, compared with $17.1 million in the third quarter of 2025 and $12.4 million in the third quarter of 2024. The nine-month figure compares with full-year 2024 revenue of $54.4 million and full-year 2025 revenue of $65.3 million.

The company attributed the revenue increase to growth across its core segments. Its contract manufacturing subsidiary, Cana Laboratories, reported